These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 26300425)
1. Comparative analysis of primary hepatocellular carcinoma with single and multiple lesions by iTRAQ-based quantitative proteomics. Xing X; Huang Y; Wang S; Chi M; Zeng Y; Chen L; Li L; Zeng J; Lin M; Han X; Liu X; Liu J J Proteomics; 2015 Oct; 128():262-71. PubMed ID: 26300425 [TBL] [Abstract][Full Text] [Related]
2. Reveal the molecular signatures of hepatocellular carcinoma with different sizes by iTRAQ based quantitative proteomics. Wang Y; Liu H; Liang D; Huang Y; Zeng Y; Xing X; Xia J; Lin M; Han X; Liao N; Liu X; Liu J J Proteomics; 2017 Jan; 150():230-241. PubMed ID: 27693406 [TBL] [Abstract][Full Text] [Related]
3. Proteome Differences between Hepatitis B Virus Genotype-B- and Genotype-C-Induced Hepatocellular Carcinoma Revealed by iTRAQ-Based Quantitative Proteomics. Wei D; Zeng Y; Xing X; Liu H; Lin M; Han X; Liu X; Liu J J Proteome Res; 2016 Feb; 15(2):487-98. PubMed ID: 26709725 [TBL] [Abstract][Full Text] [Related]
4. 17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma. Chen J; Zhuo JY; Yang F; Liu ZK; Zhou L; Xie HY; Xu X; Zheng SS Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):220-226. PubMed ID: 29748147 [TBL] [Abstract][Full Text] [Related]
5. Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma. Qi Y; Xu F; Chen L; Li Y; Xu Z; Zhang Y; Wei W; Su N; Zhang T; Fan F; Wang X; Qin X; Zhang L; Liu Y; Xu P Oncotarget; 2016 Oct; 7(42):68242-68252. PubMed ID: 27626164 [TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery. Niu D; Feng H; Chen WN J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222 [TBL] [Abstract][Full Text] [Related]
7. Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma. Xu X; Liu Z; Wang J; Xie H; Li J; Cao J; Zhou L; Zheng S Oncotarget; 2016 Mar; 7(12):13730-41. PubMed ID: 26883192 [TBL] [Abstract][Full Text] [Related]
8. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors. Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011 [TBL] [Abstract][Full Text] [Related]
9. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Luk JM; Lam CT; Siu AF; Lam BY; Ng IO; Hu MY; Che CM; Fan ST Proteomics; 2006 Feb; 6(3):1049-57. PubMed ID: 16400691 [TBL] [Abstract][Full Text] [Related]
10. Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma. Naboulsi W; Megger DA; Bracht T; Kohl M; Turewicz M; Eisenacher M; Voss DM; Schlaak JF; Hoffmann AC; Weber F; Baba HA; Meyer HE; Sitek B J Proteome Res; 2016 Jan; 15(1):38-47. PubMed ID: 26626371 [TBL] [Abstract][Full Text] [Related]
11. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. Minagawa H; Honda M; Miyazaki K; Tabuse Y; Teramoto R; Yamashita T; Nishino R; Takatori H; Ueda T; Kamijo K; Kaneko S Biochem Biophys Res Commun; 2008 Feb; 366(1):186-92. PubMed ID: 18060859 [TBL] [Abstract][Full Text] [Related]
12. Quantitative proteomics reveal up-regulated protein expression of the SET complex associated with hepatocellular carcinoma. Li C; Ruan HQ; Liu YS; Xu MJ; Dai J; Sheng QH; Tan YX; Yao ZZ; Wang HY; Wu JR; Zeng R J Proteome Res; 2012 Feb; 11(2):871-85. PubMed ID: 22082227 [TBL] [Abstract][Full Text] [Related]
13. A secretomic study on human hepatocellular carcinoma multiple drug-resistant cell lines. Xiang Y; Liu Y; Yang Y; Hu H; Hu P; Ren H; Zhang D Oncol Rep; 2015 Sep; 34(3):1249-60. PubMed ID: 26151126 [TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling. Ueda T; Honda M; Horimoto K; Aburatani S; Saito S; Yamashita T; Sakai Y; Nakamura M; Takatori H; Sunagozaka H; Kaneko S Genomics; 2013 Apr; 101(4):238-48. PubMed ID: 23485556 [TBL] [Abstract][Full Text] [Related]
15. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951 [TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach. Chiou SH; Lee KT Kaohsiung J Med Sci; 2016 Nov; 32(11):535-544. PubMed ID: 27847095 [TBL] [Abstract][Full Text] [Related]
17. Proteomic Characterization of Annexin l (ANX1) and Heat Shock Protein 27 (HSP27) as Biomarkers for Invasive Hepatocellular Carcinoma Cells. Wang RC; Huang CY; Pan TL; Chen WY; Ho CT; Liu TZ; Chang YJ PLoS One; 2015; 10(10):e0139232. PubMed ID: 26431426 [TBL] [Abstract][Full Text] [Related]
18. Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma. Zhang D; Lim SG; Koay ES Int J Oncol; 2007 Sep; 31(3):577-84. PubMed ID: 17671684 [TBL] [Abstract][Full Text] [Related]
19. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Orimo T; Ojima H; Hiraoka N; Saito S; Kosuge T; Kakisaka T; Yokoo H; Nakanishi K; Kamiyama T; Todo S; Hirohashi S; Kondo T Hepatology; 2008 Dec; 48(6):1851-63. PubMed ID: 18937283 [TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomics by SWATH-MS reveals sophisticated metabolic reprogramming in hepatocellular carcinoma tissues. Gao Y; Wang X; Sang Z; Li Z; Liu F; Mao J; Yan D; Zhao Y; Wang H; Li P; Ying X; Zhang X; He K; Wang H Sci Rep; 2017 Apr; 7():45913. PubMed ID: 28378759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]